Keros Therapeutics (NASDAQ: KROS) net income
Keros Therapeutics reported a net profit of $87.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $187.4m. Its net margin was 35.7%. Earnings per share were $2.34.
Fiscal 2025 is the highest of the 7 fiscal years on record for Keros Therapeutics. It reported a loss in 6 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $87.0m | — | 35.7% | $2.34 |
| 2024 | −$187.4m | — | −5,277.5% | −$5.00 |
| 2023 | −$153.0m | — | −101,319.2% | −$5.20 |
| 2022 | −$104.7m | — | — | −$4.15 |
| 2021 | −$58.7m | — | −292.3% | −$2.52 |
| 2020 | −$45.4m | — | — | −$2.93 |
| 2019 | −$12.3m | — | −123.4% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Keros Therapeutics net income compared with its sector
By net income for its latest fiscal year, Keros Therapeutics ranks 117th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Keros Therapeutics, 35.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 115th | Addus HomeCare | $95.9m | 6.7% |
| 116th | Embecta | $95.4m | 8.8% |
| 117th | Keros Therapeutics | $87.0m | 35.7% |
| 118th | Zevra Therapeutics | $83.2m | 78.2% |
| 119th | ANI Pharmaceuticals | $78.3m | 8.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Keros Therapeutics
- How much did Keros Therapeutics earn in fiscal 2025?
- Keros Therapeutics reported a net profit of $87.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $187.4m.
- What are the earnings per share of Keros Therapeutics?
- They were $2.34 in fiscal 2025, compared with −$5.00 in fiscal 2024.
- What is the net margin of Keros Therapeutics?
- In fiscal 2025 its net profit was 35.7% of its revenue.
- What was the most profitable year for Keros Therapeutics?
- Of its last 7 fiscal years, fiscal 2025, with $87.0m.
- Where does Keros Therapeutics rank in its sector by net income?
- It ranks 117th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Keros Therapeutics come from?
- From the annual report (Form 10-K) that Keros Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Keros Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Keros Therapeutics: the Keros Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.